2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 270

Disease Burden Is Comparable in Children with Enthesitis-Related Arthritis and Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 1383

Disease Characteristics and RA Development in Undifferentiated Arthritis: A 2-Year Follow-up Study of 413 Patients with Arthritis of Less Than 16 Weeks Duration
Abstract Number: 2598

Disease Characteristics Associated with the Presence of Dactylitis in Patients with EARLY Spondyloarthritis: Results from Esperenza Cohort
Abstract Number: 1386

Disease Flares during 10 Year Follow-up in Patients with Rheumatoid Arthritis Are Associated with Joint Damage Progression and Disability
Abstract Number: 1911

Disease Modifying Anti-Rheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients with Early Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Number: 1636

Disease Phenotype Is Associated with TH1, TH2 and TH17 Cytokines in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 945

Disease Remission Reduces Risk of Heart Failure in Rheumatoid Arthritis Patients Independent of Treatment Strategy
Abstract Number: 1534

Disease Severity and Treatment of Rheumatoid Arthritis: A Comparative Study Between Sudan and Sweden
Abstract Number: 1673

Disease Specific Quality of Life in Patients with Lupus Nephritis
Abstract Number: 1518

Disentangling the Effects of Tocilizumab on Neutrophil Survival and Function
Abstract Number: 1955

Disparity in Internalisation of Monoclonal Antibodies Targeting B Cell Antigens and Regulation By Fc Gamma Receptor IIb: Implications for Targeted Therapy in SLE
Abstract Number: 2281

Dissecting the Heterogeneity of Macrophage Activation Syndrome
Abstract Number: 751

Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis
Abstract Number: 1609

Dissection of the Type I Interferon Response in Systemic Lupus Erythematosus : Serum IFNα Is Elevated in Lupus Nephritis and Correlates with IFN Score; IFNβ Is Elevated in Mucocutaneous Disease
Abstract Number: 657

Distinct Contributions of C1q and C3 in Preventing Immunogenicity of Apoptotic Cells in Lupus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].